Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer
Polyploid giant cancer cell from triple-negative breast cancer
Photo courtesy of NCI Visuals Online
Patients with advanced solid tumors may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Christina Annunziata, M.D., Ph.D., of the Women’s Malignancies Branch is leading the Center for Cancer Research’s participation in the study of a new treatment for advanced solid tumors. Tumor cells have proteins on their surface called carcinoembryonic antigen-related cell adhesion molecules, or CEACAMs. These CEACAMs play a role in how tumors grow, develop a blood supply and spread to other parts of the body. CEACAMs also block immune cells such as T cells and natural killer cells from attacking tumors. NEO-201 is a preparation derived from human tumor tissue. NEO-201 binds to a modified version of CEACAMs expressed on the cancer cells and may cause cancer cells to die by blocking the CEACAMs. NEO-201 also helps to bring certain immune cells to the tumor, increasing their natural function of attacking cancer cells. Investigators on this study want to determine the highest dose of NEO-201 that can be given to patients with solid tumors without causing serious side effects.
Clinicaltrials.gov identifier: NCT03476681
NCI Protocol ID: NCI-18-C-0147
Official Title: Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid Tumors
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.11/2018